<DOC>
	<DOCNO>NCT03047616</DOCNO>
	<brief_summary>Several immune checkpoint inhibitor target PD-1 pathway develop clinical trial show approximately 20 % durable response unselected patient advance non-small cell lung cancer ( NSCLC ) . At moment , clear biomarker exist accurately predict anti-PD1/PDL1 tumor responsiveness . The goal study broadly discover evaluate utility blood base biomarkers use measure predict response immunotherapy patient lung cancer .</brief_summary>
	<brief_title>A Pilot Study Develop Predictive Biomarkers Response Immunotherapy Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Advanced Metastatic NSCLC Scheduled initiate immune checkpoint inhibitor Age &gt; = 18 year Able provide inform consent Other , unrelated , concomitant active , invasive malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>